Romuald Corbau
Direttore Tecnico/Scientifico/R&S presso ADVERUM BIOTECHNOLOGIES, INC.
Profilo
Romuald Corbau is currently the Chief Scientific Officer at Adverum Biotechnologies, Inc. He previously held the same position at Freeline Therapeutics Holdings Plc from 2020 to 2021.
Additionally, he served as the Chief Scientific Officer at GenEdit, Inc. Dr. Corbau is a graduate of Université des Sciences et Technologies de Lille.
Posizioni attive di Romuald Corbau
| Società | Posizione | Inizio |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Direttore Tecnico/Scientifico/R&S | 29/01/2024 |
Precedenti posizioni note di Romuald Corbau
| Società | Posizione | Fine |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Direttore Tecnico/Scientifico/R&S | 20/08/2021 |
GenEdit, Inc.
 GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Romuald Corbau
| Université des Sciences et Technologies de Lille | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
GenEdit, Inc.
GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Romuald Corbau